Lifeboat Foundation

Researchers used AI to analyze genes and discovered that aging is caused by unbalanced genes.

Researchers have discovered a breakthrough in what causes people to age. The research team, from Northwestern University in Evanston, Illinois, found a previously unknown factor that leads to aging.

The research team used AI to analyze tissue samples.

Continue reading “A new discovery in genes could help researchers understand longevity” »

In a new study published by Alzheimer’s & Dementia, scientists from Rush University and Tufts University were the first to compare cognitive decline factors to vitamin D concentrations not only in the blood, but in the brain as well.

Researchers analyzed participants of the Rush Memory and Aging Project (MAP)—an ongoing longitudinal study that aims to identify risk factors for Alzheimer’s disease and other cognitive decline disorders—before and after death to see how their vitamin D levels impacted cognitive function in their later years.

Free of known dementia at the time of enrollment, all MAP participants agreed to participate in annual evaluations and organ donation when they died. In this study, the average age of participants was 92 at the time of death.

By Joe Bennett.

Methylation tests have proven themselves to be the world’s most accurate form of biological age tests, along with being the most accurate form of life expectancy prediction to date. Unfortunately up until very recently these tests have largely been confirmed to only be available to those in the scientific community, or those with especially deep pockets. However, this is no longer the case, as this Christmas Steve Horvath’s Clock Foundation is offering a DNA methylation age test (often referred to as a GrimAge test) for the unbelievably low price of $175. This is a remarkably low price considering that last year these tests would normally be at least $450, and were not widely available at the best of times.

A Dyson Sphere is a megastructure that has not yet been built. Scientists conceive of it as a giant shell that encloses the sun.

Hypothetically, the Dyson Sphere will be lined with mirrors and solar panels that will collect the energy from the sun. This would be an unimaginable amount of energy.

In theory, the Dyson Sphere would be large enough that it could be a habitable place for humans and it would act as an artificial biosphere in the case that Earth’s supplies have dwindled. It would be a way to ensure survival for the human race.

In this video, we’ll discuss whether or not humans should be immortal. We’ll look at the benefits and drawbacks of immortality, and weigh the pros and cons of living forever.

Does living forever sound like a desirable goal? Or is it something you’d rather not risk putting your health and wellbeing at risk? Let’s discuss in this video!

Researchers use the device to study heart attacks and hope to test new heart medications.

Researchers have developed a device that can mimic aspects of a heart attack with hopes of using the device to test and develop novel heart medications. The research team, from the University of Southern California Alfred E. Mann Department of Biomedical Engineering in the U.S., created the tool, which they call a “heart attack on a chip.”

The study was published in the journal Science Advances.

Continue reading “A ‘heart attack on a chip’ device could lead to treatments for cardiovascular disease” »

Frankly I’m pretty stoked about getting my brain inside a computer and living forever.

Robin Mansukhani, CEO of Deciduous Therapeutics at Rejuvenation Startup Summit 2022.

Connect to Forever Healthy:
* Videos: https://forever-healthy.org/videos/
* News: https://forever-healthy.org/news/
* LinkedIn: https://www.linkedin.com/company/forever-healthy-foundation/

Biotech startup Lucy Therapeutics is developing mitochondrial-based small molecule therapies for neurological diseases and recently revealed the first two drugs to emerge from its lead programme targeting Parkinson’s. The company, which takes its name from the 3.2-million-year-old fossil of an ancestor of humankind, presented “promising preclinical data” at the Michael J Fox Foundation’s Parkinson’s Disease Therapeutics Conference in October.

The data shown by Lucy Therapeutics demonstrated that its compounds were able to reverse mitochondrial dysfunctions linked to Parkinson’s. In cellular models of the disease, the drugs boosted levels of cellular energy molecule ATP, prevented the death of neurons, and reduced levels of other hallmarks of Parkinson’s, including a-synuclein.

Longevity. Technology: Mitochondria are widely known as the ‘power generators’ within our cells, and their dysfunction has been linked to a range of age-related diseases. But the role of mitochondria extends beyond cellular energy as they also dictate many of a cell’s key functions. Lucy Therapeutics was founded on the hypothesis that diseases with rate-limiting steps involving mitochondrial dysfunction can potentially be treated by modulating key mitochondrial protein targets. To find out more, we caught up with the company’s founder and CEO, Dr Amy Ripka.